Risk Factors for Lymph Node Metastasis in Stage pT1 Invasive Lung Adenocarcinoma

Abstract

Objective

To analyze the risk factors for lymph node metastasis (LNM) in patients with stage pT1 lung adenocarcinoma to select a more appropriate surgical option.

Methods

In this retrospective study, 294 patients with postoperative pathologically confirmed stage pT1 invasive lung adenocarcinoma were collected and divided into two groups according to whether they had mediastinal or hilar LNM. Patient tumor imaging, pathological features and gene mutations were analyzed, and risk factors that might predict LNM were derived via univariate and multivariate logistic analyses. LNM-related variables were screened by Boruta and least absolute shrinkage and selection operator regression analysis.

Results

Among the 294 patients, 45 (15.3%) had positive mediastinal or hilar lymph nodes. There were no significant differences between the two groups in terms of sex, age, or underlying disease. The difference in the percentage of solidity between the two groups was significant, with the higer percentage group showing a more significant difference. The results of multivariate logistic analysis revealed that a high percentage of solid components and wild-type epidermal growth factor receptor (EGFR) were risk factors for LNM. The nomogram for predicting LNM included the consolidation tumor ratio, tumor size, micropapillary and EGFR, with an area under the curve of 93.4% (95% CI: 88.7–99.1) in the derivation cohort and 92.3% (95% CI: 84.6–99.9) in the validation cohort.

Conclusions

A high proportion of solid components and wild-type EGFR were risk factors for pT1 stage lung adenocarcinoma, suggesting that the choice of lung segmentectomy needs to be evaluated and selected more cautiously.

Keywords

Lung adenocarcinoma / Lymph node metastasis / Lung segmentectomy / Ground-glass nodules / Epidermal growth factor receptor

References

[1] SungH, FerlayJ, SiegelRL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] TravisWD, BrambillaE, NoguchiM, et al.. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol, 2011, 6(2): 244-285.

[3] SiegelRL, GiaquintoAN. Jemal A Cancer statistics, 2024. CA Cancer J Clin, 2024, 74(1): 12-49.

[4] TanakaK, TsutaniY, WakabayashiM, et al.. Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol, 2020, 50(9): 1076-1079.

[5] NakazawaS, ShimizuK, MogiA, et al.. VATS segmentectomy: past, present, and future. Gen Thorac Cardiovasc Surg, 2018, 66(2): 81-90.

[6] SuzukiK, SajiH, AokageK, et al.. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg, 2019, 158(3): 895-907.

[7] HattoriA, SuzukiK, TakamochiK, et al.. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial. Lancet Respir Med, 2024, 12(2): 105-116.

[8] SajiH, OkadaM, TsuboiM, et al.. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, 2022, 399(10335): 1607-1617.

[9] YueS, LiS, HuangX, et al.. Machine learning for the prediction of acute kidney injury in patients with sepsis. J Transl Med, 2022, 201215.

[10] Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351:h3868.

[11] HendriksLE, RemonJ, Faivre-FinnC, et al.. Non-small-cell lung cancer. Nat Rev Dis Primers, 2024, 10171.

[12] HanL, LeeC, PangH, et al.. Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. Lung Cancer (Amsterdam, Netherlands), 2017, 114: 79-89.

[13] LavinY, KobayashiS, LeaderA, et al.. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell, 2017, 169(4): 750-765.e717.

[14] Hu DD, Chen HL, Lou LM, et al. SKA3 promotes lung adenocarcinoma metastasis through the EGFR-PI3K-Akt axis. Biosci Rep. 2020;40(2):BSR20194335.

[15] ChurchillED, SweetRH, SoutterL, et al.. The surgical management of carcinoma of the lung; a study of the cases treated at the Massachusetts General Hospital from 1930 to 1950. J Thorac Surg, 1950, 20(3): 349-365.

[16] Ginsberg R, Rubinstein L. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–622; discussion 622–623.

[17] ChanEG, ChanPG, MazurSN, et al.. Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non-small cell lung cancer. J Thorac Cardiovasc Surg, 2021, 161(5): 1639-1648.e1632.

[18] WenZ, ZhaoY, FuF, et al.. Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter. J Cancer Res Clin Oncol, 2020, 146(6): 1603-1613.

[19] Kagimoto A, Tsutani Y, Shimada Y, et al. Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. Eur J Cardiothorac Surg. 2022;62(2):ezac055.

[20] LiuC, YangZ, LiY, et al.. Intentional wedge resection versus segmentectomy for  =2 cm ground-glass-opacity-dominant non-small cell lung cancer: a real-world study using inverse probability of treatment weighting. Int J Surg, 2024, 110(7): 4231-4239.

[21] TsubokawaN, MimaeT, SaekiA, et al.. Feasibility and comparative prognosis of segmentectomy versus lobectomy in centrally located small and solid dominant cN0 non-small cell lung cancer. J Thorac Cardiovasc Surg, 2024, S0022–5223(24): 00538-545

[22] KoikeT, KoikeT, SatoS, et al.. Lobectomy and limited resection in small-sized peripheral non-small cell lung cancer. J Thorac Dis, 2016, 8(11): 3265-3274.

[23] Zheng YZ, Zhai WY, Zhao J, et al. Oncologic outcomes of lobectomy vs. segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis. J Thorac Dis. 2020;12(6):3178–3187.

[24] XiaoF, YuQ, ZhangZ, et al.. Novel perspective to evaluate the safety of segmentectomy: clinical significance of lobar and segmental lymph node metastasis in cT1N0M0 lung adenocarcinoma. Eur J Cardiothorac Surg, 2018, 53(1): 228-234.

[25] MatsumuraY, HishidaT, YoshidaJ, et al.. Reasonable extent of lymph node dissection in intentional segmentectomy for small-sized peripheral non-small-cell lung cancer: from the clinicopathological findings of patients who underwent lobectomy with systematic lymph node dissection. J Thorac Oncol, 2012, 7(11): 1691-1697.

[26] NieY, GaoW, LiN, et al.. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma. World J Surg Oncol, 2017, 15155.

[27] EnomotoY, TakadaK, HagiwaraE, et al.. Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations. Respir Investig, 2013, 51(3): 153-157.

[28] JiaX, LiJ, ZhaoH, et al.. Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer. Genet Mol Res, 2015, 14(3): 11006-11012.

[29] GuerreraF, RenaudS, TabbóF, et al.. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. Eur J Cardiothorac Surg, 2017, 51(4): 680-688.

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology